GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Financial Strength

OptimizeRx (OptimizeRx) Financial Strength : 5 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Financial Strength?

OptimizeRx has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

OptimizeRx did not have earnings to cover the interest expense. OptimizeRx's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.32. As of today, OptimizeRx's Altman Z-Score is 1.65.


Competitive Comparison of OptimizeRx's Financial Strength

For the Health Information Services subindustry, OptimizeRx's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptimizeRx's Financial Strength Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Financial Strength distribution charts can be found below:

* The bar in red indicates where OptimizeRx's Financial Strength falls into.



OptimizeRx Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

OptimizeRx's Interest Expense for the months ended in Dec. 2023 was $-1.45 Mil. Its Operating Income for the months ended in Dec. 2023 was $-2.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $34.60 Mil.

OptimizeRx's Interest Coverage for the quarter that ended in Dec. 2023 is

OptimizeRx did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

OptimizeRx's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.222 + 34.602) / 113.476
=0.32

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

OptimizeRx has a Z-score of 1.65, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 1.65 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OptimizeRx  (NAS:OPRX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

OptimizeRx has the Financial Strength Rank of 5.


OptimizeRx Financial Strength Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022